Precigen’s First FDA-Approved Immunotherapy Marks a Turning Point for RRP Patients and Community Advocacy
Market Chameleon (Fri, 12-Jun 10:33 AM)
PAPZIMEOS Drives Revenue Surge and Broader Patient Access: Precigen's Q1 2026 Update Highlights Major Momentum
Market Chameleon (Thu, 14-May 10:16 AM)
PAPZIMEOS Drives Revenue Growth and Broad Patient Uptake in Precigen’s First Full Quarter Post-Launch
Market Chameleon (Thu, 14-May 7:06 AM)
